A bacteriocin expression platform for targeting pathogenic bacterial species

Nat Commun. 2024 Jul 27;15(1):6332. doi: 10.1038/s41467-024-50591-8.

Abstract

Bacteriocins are antimicrobial peptides that are naturally produced by many bacteria. They hold great potential in the fight against antibiotic resistant bacteria, including ESKAPE pathogens. Engineered live biotherapeutic products (eLBPs) that secrete bacteriocins can be created to deliver targeted bacteriocin production. Here we develop a modular bacteriocin secretion platform that can be used to express and secrete multiple bacteriocins from non-pathogenic Escherichia coli host strains. As a proof of concept we create Enterocin A (EntA) and Enterocin B (EntB) secreting strains that show strong antimicrobial activity against Enterococcus faecalis and Enterococcus faecium in vitro, and characterise this activity in both solid culture and liquid co-culture. We then develop a Lotka-Volterra model that can be used to capture the interactions of these competitor strains. We show that simultaneous exposure to EntA and EntB can delay Enterococcus growth. Our system has the potential to be used as an eLBP to secrete additional bacteriocins for the targeted killing of pathogenic bacteria.

MeSH terms

  • Anti-Bacterial Agents* / pharmacology
  • Bacteriocins* / biosynthesis
  • Bacteriocins* / metabolism
  • Bacteriocins* / pharmacology
  • Coculture Techniques
  • Enterococcus faecalis* / drug effects
  • Enterococcus faecalis* / genetics
  • Enterococcus faecalis* / metabolism
  • Enterococcus faecium* / drug effects
  • Enterococcus faecium* / genetics
  • Enterococcus faecium* / metabolism
  • Escherichia coli* / drug effects
  • Escherichia coli* / genetics
  • Escherichia coli* / metabolism
  • Microbial Sensitivity Tests

Substances

  • Bacteriocins
  • Anti-Bacterial Agents
  • enterocin A
  • enterocin B